The BTK/ITK inhibitor ibrutinib reprogrammes the tumour-induced immunosuppressive population of myeloid lineage (MDSCs) into mature DCs by blocking BTK, increases the proportion of mature DCs in the tumour and lymphoid organs, and promotes antitumour T cell activity. Here, BTK is linked to neoplasm.